Alexander I Spira MD, PhD, FACP, FASCO

Virginia Cancer Specialists' Physicians

Alexander I Spira MD, PhD,  FACP, FASCO Headshot

Getting a diagnosis of cancer is the most challenging thing any patient and family will have to go through. My job is to provide the most comprehensive options for patients, with state-of-the-art care and compassion.

Work and Credentials:

Primary Location

Fairfax Office

Position

Medical Oncologist

Board Certification

Medical Oncology and Internal Medicine

Fellowship

Johns Hopkins Hospital, Medical Oncology

Internship

Hospital of the University of Pennsylvania

Residency

Hospital of the University of Pennsylvania

Medical School

New York University School of Medicine

College

Harvard University

Special Interests

Thoracic, sarcomas, clinical trials

Physician Bio

Alexander I Spira MD, PhD, FACP, FASCO

Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program, Clinical Assistant Professor, Johns Hopkins

Dr. Alexander Spira earned his medical degree from the New York University School of Medicine. He then went on to complete his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. During his training, Dr. Spira was granted many awards and honors, and he completed several specialized fellowship programs. Among these honors were the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993- 1995) and Harvard University Scholarship (1987-1990). Dr. Spira has also received his PhD from the New York School of Arts and Sciences.

As Director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program, Dr. Spira is actively involved in advancing medicine and offering targeted treatment options for patients. Although his research interests are numerous, Dr. Spira particularly enjoys studying immunotherapy, personalized medicine, GI, thoracic and lung cancer and sarcomas. Dr. Spira is also Co-Chair of the USOncology Thoracic Oncology Committee, Chair of the USOncology Research Executive Committee, and member of the USOncology National Policy Board Executive Committee. Dr. Spira is a faculty member at Johns Hopkins School of Medicine, and serves as Assistant Professor of Oncology.

Throughout his career, Dr. Spira has been recognized as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious “Castle Connolly America’s Top Doctor” award. In his spare time, Dr. Spira enjoys spending time with his family, coaching children’s sports, cycling, and cheering on his favorite New York sports teams.

Recognition

Patient Testimonials

Physician Videos:

'
'

Physician Publications

July 13, 2022

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Read More
June 3, 2022

ASCO 2022 | KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC

Read More
June 3, 2022

Adagrasib Induces Promising Efficacy, Deep Responses in KRAS G12C NSCLC

Read More

More Publications by Alexander I Spira MD, PhD, FACP, FASCO

June 3, 2022

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Read More
June 3, 2022

KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients

Read More
June 3, 2022

Dr. Spira on the Potential Role of Adagrasib in NSCLC

Read More
April 8, 2022

Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Read More
March 15, 2022

Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study

Read More
December 1, 2021

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer

Read More
December 1, 2021

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Read More
October 18, 2021

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer

Read More
September 13, 2021

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer

Read More
August 2, 2021

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Read More
July 1, 2021

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

Read More
July 1, 2021

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

Read More
May 24, 2021

Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real-world retrospective observational study

Read More
May 3, 2021

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies

Read More
May 1, 2021

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

Read More
February 25, 2021

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Read More
January 29, 2021

Datopotamab deruxtecan and Enhertu show promising early clinical activity in patients with advanced non-small cell lung cancer

Read More
January 29, 2021

Datopotamab Deruxtecan Elicits Early Antitumor Activity in Relapsed/Refractory Metastatic NSCLC

Read More
December 26, 2020

Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)

Read More
September 1, 2020

Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cance

Read More
August 11, 2020

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Read More
June 7, 2020

Camidanlumab Tesirine, an Antibody-Drug Conjugate, in Relapsed/Refractory CD25-positive Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia: A Phase I Study

Read More
April 7, 2020

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue SarcomasThe ANNOUNCE Randomized Clinical Trial

Read More
March 21, 2020

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Read More
October 1, 2019

A review of canakinumab and its therapeutic potential for non-small cell lung cancer.

Read More
August 1, 2019

Detection of NRG1 Gene Fusions in Solid Tumors.

Read More
August 1, 2019

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.

Read More
September 25, 2018

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

Read More
March 9, 2016

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Read More
September 14, 2015

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

Read More
June 3, 2013

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

Read More
February 1, 2013

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Read More
January 2, 2013

Expert Insight: Adjuvant Therapy Fails for High-Risk Soft Tissue Sarcoma

Read More
June 1, 2012

Phase II study of two eribulin regimens in combination with erlotinib in patients (pts) with previously treated advanced non-small cell lung cancer

Read More
April 16, 2012

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

Read More
January 1, 2012

Clinical trial design in the age of molecular profiling.

Read More
September 8, 2011

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

Read More
June 1, 2011

Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients

Read More
June 1, 2011

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

Read More
June 1, 2011

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

Read More
December 4, 2010

Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma.

Read More
December 1, 2010

Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer.

Read More
December 3, 2009

Use of an ex vivo multiplexed signal pathway inhibitor treatment to reveal sensitivity of myeloma and nonmyeloma bone marrow cell populations.

Read More
December 1, 2009

Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.

Read More
January 22, 2004

Multidisciplinary Management of Lung Cancer

Read More
January 1, 2002

The use of Chemotherapy in Soft Tissue Sarcomas

Read More